Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

M. Michelle Xu, Y. Pu, R. R. Weichselbaum, Y. X. Fu

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8+ T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.

Original languageEnglish (US)
Pages (from-to)585-592
Number of pages8
JournalOncogene
Volume36
Issue number5
DOIs
StatePublished - Feb 2 2017

Fingerprint

Immunotherapy
Antibodies
Neoplasms
Therapeutics
Cross-Priming
T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Drug Therapy
Interferon Type I
Radiation Effects
Neoplasm Antigens
DNA Repair
DNA Damage
Immune System
Radiotherapy
Survival Rate
Radiation
Recurrence
Growth

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. / Xu, M. Michelle; Pu, Y.; Weichselbaum, R. R.; Fu, Y. X.

In: Oncogene, Vol. 36, No. 5, 02.02.2017, p. 585-592.

Research output: Contribution to journalReview article

Xu, M. Michelle ; Pu, Y. ; Weichselbaum, R. R. ; Fu, Y. X. / Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. In: Oncogene. 2017 ; Vol. 36, No. 5. pp. 585-592.
@article{2cf5bb18e69245df8466a5c27588dd4a,
title = "Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy",
abstract = "In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8+ T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.",
author = "Xu, {M. Michelle} and Y. Pu and Weichselbaum, {R. R.} and Fu, {Y. X.}",
year = "2017",
month = "2",
day = "2",
doi = "10.1038/onc.2016.231",
language = "English (US)",
volume = "36",
pages = "585--592",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

AU - Xu, M. Michelle

AU - Pu, Y.

AU - Weichselbaum, R. R.

AU - Fu, Y. X.

PY - 2017/2/2

Y1 - 2017/2/2

N2 - In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8+ T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.

AB - In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8+ T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=84978763017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978763017&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.231

DO - 10.1038/onc.2016.231

M3 - Review article

VL - 36

SP - 585

EP - 592

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 5

ER -